VERAXA Biotech Stock in Focus as Lead Cancer Program Reaches Development Milestone
By
Exec-Edge
| July 02, 2026, 6:40 PM
By Karen Roman
VERAXA Biotech AG (Nasdaq: VRXA) said it started cell line development for its lead BiTAC T-cell engager program, collaborating with ATUM to apply proprietary technology for stable clonal cell line generation.
“Today’s news underscores our commitment to accelerate the development path of our growing BiTAC-TCE portfolio,” said Christoph Erkel, Ph.D., VERAXA’s Vice President Research and Development. “Initiating cell line development with ATUM is an important next step for our lead BiTAC-TCE program following the encouraging preclinical data we presented at AACR.”
Register for our weekly newsletter HERE
READ MORE
VERAXA Biotech Expands R&D Hub in Heidelberg as Programs Advance Towards Clinical Development
Contact:
Click HERE to follow us on LinkedIn
The post VERAXA Biotech Stock in Focus as Lead Cancer Program Reaches Development Milestone appeared first on ExecEdge.
Mentioned In This Article
Latest News
| Oct-21 | |
| Oct-13 | |
| Oct-13 | |
| Oct-07 | |
| Oct-07 | |
| Oct-07 | |
| Oct-07 | |
| Sep-24 | |
| Sep-22 | |
| Sep-18 | |
| Sep-16 | |
| Sep-09 | |
| Sep-08 | |
| Sep-04 | |
| Aug-28 |
